The purpose of this study is to assess the safety and efficacy of injectable collagen scaffold combined with human umbilical cord-derived mesenchymal stem cells (HUC-MSCs) transplantation in patients with Decompensated Cirrhosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
Patients will receive the conventional therapy.
Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
RECRUITINGImprovement of liver function measured by change in the model for end-stage liver disease (MELD) score
Time frame: 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention
Improvement of liver function measured by change in Child-Pugh score
Time frame: 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention
Change in clinical laboratory parameters of liver function
The liver function tests included serum Albumin (Alb), Cholesterol, Cholinesterase (CHE), prothrombin activity.
Time frame: 1 day, 3 day, 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention
30-Day Survival
Patients surviving more than 30 days after study registration.
Time frame: 30 days
Change in the size of liver and spleen and inner diameter of spleen portal venous
Time frame: 1 week, 2 week, 1, 3, 6, 12, 24 month after intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.